Making Every Little Bit Count: Parkinson’s Disease SHP – Neurobiology of Development and Disease.

Slides:



Advertisements
Similar presentations
Chapter 5 Opener. 5.1 Structural features of catecholamines.
Advertisements

What is Parkinson’s Disease?
Drugs That Act On The Central Nervous System SAMUEL AGUAZIM( MD)
Parkinson's Disease Animal Models and Possible Treatments.
Parkinson’s Disease (PD)
The PARticulars of Parkinson’s Disease
An Overview of Conventional and Experimental Treatments
Parkinson’s Disease Dr Rachel Cary, Warwick Hospital.
James Parkinson Born in 1755; died Lived entire life in London. Political reformer Paleontologist Physician.
Drugs Used to Treat Parkinson’s Disease By Jasmine and Morgan 11/13/03.
NEURAL TRANSMISSION Neurons Electrical and Chemical Transmission.
Parkinson’s Disease Historical Perspective  First described by British doctor James Parkinson  Identified its major symptoms and called it “the shaking.
PHL 437/Pharmacogenomics Fourth Lecture (Parkinson’s disease) By Abdelkader Ashour, Ph.D. Phone:
Paul Short, Ph.D. The Parkinson’s Coach NEUROPSYCHOLOGY OF PARKINSON’S COMMUNICATION PROBLEMS.
Alzheimer’s Disease Nicotine’s relationship and contribution to dementia.
Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.
Erica Partridge Parkinson’s Disease. Definition Aetiology PD vs Parkinsonism Symptoms and signs Differentials Investigations Management Prognosis.
Parkinson’s Disease Busra Berika Yucel
Parkinson ’ s disease. Function Anatomy of Parkinson ’ s Disease.
Parkinson’s Disease By Devin Cornford
Drugs for Parkinon’s disease Parkinson's disease –progressive tremor –Bradykinesia and rigidity –degeneration of the dopaminergic nigrostriatal pathway.
Drugs of Anti-Parkinson’s disease Department of Pharmacology Zhang Yan-mei.
Making Things Happen - 2 Motor Disorders How Your Brain Works - Week 7 Dr. Jan Schnupp HowYourBrainWorks.net.
Treatment of Parkinson’s Disease Thomas L. Davis, M.D. Associate Professor of Neurology Vanderbilt School of Medicine.
Parkinson’s Disease superKAT :).
BY: MACKENZIE SOARES ALYSSA MEDIEROS STEPHANIE GARDNER Parkinson's Disease.
Neurotransmitters, Parkinson’s disease and depression
PhD MD MBBS Faculty of Medicine Al Maarefa Colleges of Science & Technology Faculty of Medicine Al Maarefa Colleges of Science & Technology Lecture – 9:
Neurotransmitters: Catecholamines & Acetylcholine Chapters 5 & 6
Salvador Dali (Painter) Mao Zedong (Chinese Politician) Michael J Fox (Actor) Pope John Paul II Muhammad Ali (Boxer) Janet Reno (Former AG)
Treatment of Parkinson’s Disease Christopher Buchanan CHEM 5398/Buynak April 3, 2007.
Neurotransmitters: Catecholamines & Acetylcholine Chapters 5 & 6 Catecholamines  Dopamine  Norepinephrine  Epinephrine Acetylcholine Serotonin Glutamate.
DOPAMINE HYPOTHESIS.
Slide 1 Mosby items and derived items © 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 15 Drugs Used for Parkinson’s Disease.
Mitochondria in the etiology and pathogenesis of Parkinson's disease
1 Parkinson’s Disease (PD): Levodopa Drug Treatment Presenter: Pedro Da Silva Date: February 27, 2007.
Biological Explanations for Schizophrenia
Α-synuclein transgenic mouse models of Parkinson’s disease Michelle Maurer December 2015.
Parkinson’s Disease Sheila Mulhern. Parkinson’s Disease Stats (PDF)  One million Americans live with Parkinson's disease, - more than the combined number.
Drugs Used for Parkinson’s Disease Chapter 15 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
Pathogenesis and pathology of parkinsonism
ANTI- PARKINSONISM Dr: Samah Gaafar Al-shaygi.  Neurodegenerative diseases.  Dopamenergic neurones in substantia nigra.  Environmental* genetic factors.
 Parkinson’s disease is a neurodegenerative disorder first described by Dr James Parkinson, a London physician, in The underlying cause is loss.
Parkinson’s Disease Casey Wang
ANTI-PARKINSONIAN DRUGS. Parkinsonism It is a common movement disorder that involves dysfunction in the basal ganglia and associated brain structures.
Emma Hahs, Brooke Armistead, Sarah Brown, Sok Kean Khoo Department of Cell and Molecular Biology, College of Liberal Arts and Sciences, Grand Valley State.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Pharmacological Treatment of Parkinson Disease: A.
PARKINSON’S DISEASE CHAMINDA UNANTENNE RN,MS,MSN.
Parkinson’s disease by Syed Baseeruddin Alvi (09).
Drugs Used for Parkinson’s Disease
Parkinson’s Disease.
Drugs for Parkinson’s Disease
Parkinson's disease KRZYSZTOF NICPOŃ.
Treatment of Parkinson’s disease
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
DOPAMINE HYPOTHESIS.
III. Parkinson Disease.
Parkinson’s disease.
Alpha-synuclein in Parkinson's disease
ANTIPARKINSONS Drugs By Dr. Mirza Shahed Baig.
Parkinsonism and Anesthesia
Neurotransmitters.
מחלת פרקינסון מחלת פרקינסון היא מחלה Progressive.
Anti-parkinsonism Drugs
Drug induced parkinsonism
Anti-parkinsonism Drugs
Parkinson's Disease Neuron
Drugs for Degenerative Diseases of the Nervous System
Eleanor H. Simpson, Christoph Kellendonk, Eric Kandel  Neuron 
Neurodegenerative diseases
Presentation transcript:

Making Every Little Bit Count: Parkinson’s Disease SHP – Neurobiology of Development and Disease

Parkinson’s Disease Initially described symptomatically by Dr. James Parkinson in 1817 in An Essay on the Shaking Palsy. Biochemical deficit and death of neurons was not characterized until the 1957 discovery by Arvid Carlsson that dopamine is a neurotransmitter. Symptoms: –Tremor (4-7Hz) –Rigidity –Akinesia/Bradykinesia –Postural Instability (stooped posture, lack of balance) –Dementia, memory loss –Speech problems –Facial masking PD appears to occur in approximately 2% of individuals

PD is Caused by a Loss of Midbrain Dopaminergic Neurons Disease becomes manifest when ~80% of dopamine lost and 60% of neurons are lost. Dopaminergic dropout can be seen in the destaining of neuromelanin in the substantia nigra Some loss of neurons is also observed in noradrenergic (locus coeruleus), serotonergic (raphe), and cholinergic, olfactory bulb and autonomic nervous system. PD Normal

Mesolimbic pathway: project from the ventral tegmental area (VTA) to the cerebral cortex, nucleus accumbens, and the hippocampus. This system appears to be involved in the dopaminergic arm of addiction. Overactivation of dopamine in this circuit is associated with schizophrenia. Nigrostriatal pathway: project from the substantia nigra to the striatum This is the zone where most loss of neurons occurs in PD Dopaminergic Circuits

Positron Emission Tomography (PET)

PET Scan Reveals Loss of Dopamine Receptors in the Brain Injecting patients with 18 F-dopamine allows quantification of dopaminergic receptors in the brain. PD patients have a great diminishment of receptors in the brain (as a results of DA neuron death).

MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Metabolized into MPP+, which kills dopaminergic neurons in the substantia nigra by oxidative damage Discovered in 1972 when a graduate student, Barry Kidston, incorrectly synthesized the opioid MPPP and injected the product. He began displaying classic parkinsonian symptoms within 3 days. Two years later, he committed suicide and autopsy showed characteristic loss of DA neurons in the substantia nigra. In 1982, MPPP was manufactured illicitly in Santa Clara County, CA and distributed as a synthetic heroin. Soon after, a surge of clinical cases began to appear, some as young as 19 years old, displaying idiopathic, end-stage parkinsonian symptoms. These cases were ultimately linked to use of MPPP batches tainted with a byproduct of MPTP. Taken up by dopamine transporters and inhibits complex-1 of the mitochondrial transport chain. MPPP MPTP

Genes linked with PD

Pathways that Are Involved with PD Moore et al, 2005

Lewy Bodies Histological analysis of PD brains reveals inclusion bodies in dopaminergic neurons, known as Lewy bodies. These appear to be primarily constituted of alpha-synuclein, parkin, ubiquitin, and neurofilaments.

The gene Parkin, originally identified in a consanguineous Pakinstani family known to have congenital early onset PD. A mutation in parkin has been found in 50% of the cases of early onset PD. Parkin, containing a RING finger domain, is a E3 ubiquitin ligase involved in the ligation of ubiquitin to proteins for proteosomal degradation targeting. Dysfunction of this gene is thought to allow abnormally folded and old proteins to inappropriately linger and accumulate in the cell, perhaps leading to aggregation. Parkin Mutation Linked to PD

Treatment Initiatives: Enhancement of neurotransmitter synthesis Prevention of neurotransmitter breakdown Replacement of lost neurons Preventing inappropriate neural activity downstream

Targets in the Dopaminergic Pathway

Levodopa (L-dopa) A prodrug that is administered to PD patients to enhance dopamine production (since dopamine cannot cross the blood-brain-barrier) It is transported over the blood-brain barrier by the large neutral amino acid (LNAA) transporter. Only 5% of the drug reaches the brain due to conversion to dopamine by AAAV in the periphery. Its action here is associated with intense nausea. AAAV inhibitors carbidopa and benzserazide inhibit peripheral production of dopamine and increases availability for CNS.

The Distribution of Levodopa Through Biological Compartments

Disadvantages of Levodopa The half-life Levodopa is only 2hrs but ameliorates the PD symptoms for 8hrs intervals (known as the long duration effect), which is thought to be due to transmitter being stored in the DA neurons. After 2-4yrs of treatment, patients develop a “wearing off” where the drug seems to stop working in between doses. Now the effect of the drug is dependent on serum concentration (known as the short duration effect. Longterm use is associated with levodopa-induced dyskinesias. Taking too much of the drug will induce a schizophrenia- like syndrome (characterized primarily by auditory and visual hallucinations).

Dopamine Agonists Half-live of drugs are much longer than Levodopa so smoothes out drugs in the blood over time. Directly stimulates DA receptors, circumventing issues with synthesizing neurotransmitters in dying neurons. Some evidence that they may be neuroprotective.

Monoamine Oxidase Inhibitors (MAOIs) MAO is the enzyme that rapidly breaks down neurotransmitters left in the synaptic cleft. Inhibition leaves more neurotransmitter available in the synaptic cleft Selegiline is the most prescribed because it is selective for MAOIB (inhibition of MAOIA produces “cheese effect”, where sympathicomimetics in food like tyramine can induce sympathetic overdrive).

COMT Inhibitors When decarboxylation of levodopa by AAAD in the periphery is blocked COMT is the second route of inactivation levodopa to 3-OMD. Inhibiting this enzyme prevents breakdown of the drug in the periphery. Tolcapone is an example

Anticholinergics Utilized in the treatment of PD before the discovery of dopamine (anti-muscarinics). Only effective against resting tremors and do no improve bradykinesia and rigidity. The mechanism of effect is not known but is thought to act on cholinergic interneurons present in the striatum.

Deep Brain Stimulation Surgical procedure where a electrical stimulator is implanted in the chest and wires run under the skin supply current to an electrode implanted in the dysfunctional area. For PD these electrodes are implanted in the subthalamic region. Alleviation of symptoms are immediate on turning on the stimulator and are reversible when turned off.